<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02406443</url>
  </required_header>
  <id_info>
    <org_study_id>14-8616</org_study_id>
    <nct_id>NCT02406443</nct_id>
  </id_info>
  <brief_title>The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion</brief_title>
  <acronym>INDORSE</acronym>
  <official_title>Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4
      inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the
      mechanisms mediating the renal effects of DPP-4 inhibitors in humans.

      Objectives: To evaluate the effect of DPP-4 inhibition acutely (single dose) and following
      short-term therapy (28 days) on renal sodium handling and renal hemodynamics and function in
      patients with type 2 diabetes and systolic hypertension.

      Design: double-blind, randomized, placebo-controlled trial, Phase IV.

      Patient population: 32 patients with Type 2 diabetes, HbA1c (6.5%-9%), with systolic blood
      pressure ranging from 120-160 mmHg.

      Intervention: subjects will be randomized (1:1) to either sitagliptin (100 mg daily) or to
      placebo (1 tablet daily) for 28 days.

      Endpoints: Fractional excretion of sodium, renal function, and renal hemodynamics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: DPP-4 inhibition improves glycemic control, modestly reduces blood pressure and
      may also reduce albuminuria in patients with Type 2 diabetes; effects which occur without
      significantly modifying heart rate or body weight. While preclinical studies have
      demonstrated that DPP-4 inhibition acutely increases urinary sodium excretion in addition to
      other favorable renal effects (anti-inflammatory, anti-proteinuric), few studies have
      examined the renal effects of DPP-4 inhibition either acutely or following short-term therapy
      in humans with type 2 diabetes. Considering the world-wide prevalence of Type 2 diabetes and
      the increasing use of DPP-4 inhibitors amongst patients, it is important to ascertain
      potential non-glycemic effects of DPP-4 inhibitors including those within the kidney.

      Study Objectives: To determine effect(s) of DPP-4 inhibition on tubular sodium handling,
      renal hemodynamics, and renal function.

      Study Design: double-blind, randomized, placebo-controlled trial, Phase IV.

      Study Patients: 32 patients with Type 2 Diabetes and Systolic Hypertension (SBP 120-160
      mmHg).

      Endpoints: Fractional excretion of sodium, renal function (measured GFR), renal hemodynamics
      (effective renal plasma flow, filtration fraction, renal blood flow, renal vascular
      resistance), systemic hemodynamics (non-invasive cardiac monitoring), plasma neurohormones,
      urinary vasoactive mediators, markers of free radical stress.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Fractional Excretion of Sodium (FENA)</measure>
    <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
    <description>FENA at 3Hrs post-study drug administration after 1 month compared to FENA at 3Hrs post-study drug administration after 1 dose expressed as percent change, sitagliptin vs. placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glomerular Filtration Rate (GFR)</measure>
    <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
    <description>Measured GFR (Inulin Clearance) at 3Hrs post study-drug after 1 month compared to Measured GFR at 3Hrs post-study drug after 1 dose, sitagliptin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fractional Excretion of Lithium (FELi)</measure>
    <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
    <description>FELi at 3 Hr post-study drug administration after 1 month compared to FELI at 3hrs post-study drug administration after 1 dose, sitagliptin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDF-1alpha^1-67 (Intact) Measured by Immunoaffinity and Tandem Mass Spectrometry</measure>
    <time_frame>3 Hr vs. baseline after 1 dose</time_frame>
    <description>Plasma concentration of SDF-1alpha^1-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDF-1alpha^3-67 (Truncated) Measured by Tandem Mass Spectrometry With Antibody-based Affinity Enrichment</measure>
    <time_frame>3Hrs vs baseline after 1 dose</time_frame>
    <description>Plasma concentration of SDF-1alpha^3-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP), Non-invasive Cardiac Output Monitoring</measure>
    <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
    <description>SBP by Non-Invasive cardiac output monitoring at 3Hrs post- study drug administration after 1 month compared to SBP by Non-invasive cardiac output monitoring at 3Hrs after 1 dose, sitagliptin vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
    <description>ERPF (para-aminohippurate clearance) 3Hrs post-study drug administration after 1 month compared to ERPF at 3Hhrs post-study drug administration after 1 dose, sitagliptin vs placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitaglitpin</intervention_name>
    <description>Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals of 18-70 years of age,

          -  with Type 2 Diabetes,

          -  with an HbA1c (6.5%-9%),

          -  and with a systolic blood pressure (120-160 mmHg).

        Exclusion Criteria:

          -  Individuals with:

               1. Type 1 Diabetes,

               2. eGFR &lt;50mL/min/1.73m,

               3. pregnancy or breast feeding,

               4. significant cardiac, pulmonary or liver disease,

               5. prior history of pancreatitis, medullary thyroid cancer, multiple endocrine
                  neoplasia syndromes,

               6. SBP &gt;161 mmHg, 7) DBP &gt;100 mmHg,

               7. alcohol or substance abuse,

               8. states of secondary hypertension.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Lovshin, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lunenfeld Tanenbaum Reserach Institute, Divsion of Endocrinology and Metabolism, University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David I Cherney, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, University Health Network, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network - Division of Nephrology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2015</study_first_posted>
  <results_first_submitted>July 14, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2018</results_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes, DPP-4 inhibitors, renal sodium excretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental Arm</title>
          <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Arm</title>
          <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="7.6"/>
                    <measurement group_id="B2" value="59.3" spread="8.8"/>
                    <measurement group_id="B3" value="59.8" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Duration</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="3.0" upper_limit="10.0"/>
                    <measurement group_id="B2" value="8.5" lower_limit="5.5" upper_limit="14.0"/>
                    <measurement group_id="B3" value="8.0" lower_limit="4.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (%)</title>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.18" spread="0.97"/>
                    <measurement group_id="B2" value="7.31" spread="0.84"/>
                    <measurement group_id="B3" value="7.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Fractional Excretion of Sodium (FENA)</title>
        <description>FENA at 3Hrs post-study drug administration after 1 month compared to FENA at 3Hrs post-study drug administration after 1 dose expressed as percent change, sitagliptin vs. placebo</description>
        <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Fractional Excretion of Sodium (FENA)</title>
          <description>FENA at 3Hrs post-study drug administration after 1 month compared to FENA at 3Hrs post-study drug administration after 1 dose expressed as percent change, sitagliptin vs. placebo</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="43"/>
                    <measurement group_id="O2" value="-5.0" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.012</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>46</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glomerular Filtration Rate (GFR)</title>
        <description>Measured GFR (Inulin Clearance) at 3Hrs post study-drug after 1 month compared to Measured GFR at 3Hrs post-study drug after 1 dose, sitagliptin vs. placebo</description>
        <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glomerular Filtration Rate (GFR)</title>
          <description>Measured GFR (Inulin Clearance) at 3Hrs post study-drug after 1 month compared to Measured GFR at 3Hrs post-study drug after 1 dose, sitagliptin vs. placebo</description>
          <units>ml per min per 1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="20.4"/>
                    <measurement group_id="O2" value="-1.8" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>Regression, Linear</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>5.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fractional Excretion of Lithium (FELi)</title>
        <description>FELi at 3 Hr post-study drug administration after 1 month compared to FELI at 3hrs post-study drug administration after 1 dose, sitagliptin vs. placebo</description>
        <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fractional Excretion of Lithium (FELi)</title>
          <description>FELi at 3 Hr post-study drug administration after 1 month compared to FELI at 3hrs post-study drug administration after 1 dose, sitagliptin vs. placebo</description>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="55"/>
                    <measurement group_id="O2" value="7" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDF-1alpha^1-67 (Intact) Measured by Immunoaffinity and Tandem Mass Spectrometry</title>
        <description>Plasma concentration of SDF-1alpha^1-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
        <time_frame>3 Hr vs. baseline after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDF-1alpha^1-67 (Intact) Measured by Immunoaffinity and Tandem Mass Spectrometry</title>
          <description>Plasma concentration of SDF-1alpha^1-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
          <units>ng per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDF-1alpha^3-67 (Truncated) Measured by Tandem Mass Spectrometry With Antibody-based Affinity Enrichment</title>
        <description>Plasma concentration of SDF-1alpha^3-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
        <time_frame>3Hrs vs baseline after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDF-1alpha^3-67 (Truncated) Measured by Tandem Mass Spectrometry With Antibody-based Affinity Enrichment</title>
          <description>Plasma concentration of SDF-1alpha^3-67 (intact) measured by quantitative mass spectrometry methods after antibody-based affinity enrichment, sitagliptin vs. placebo</description>
          <units>ng per mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP), Non-invasive Cardiac Output Monitoring</title>
        <description>SBP by Non-Invasive cardiac output monitoring at 3Hrs post- study drug administration after 1 month compared to SBP by Non-invasive cardiac output monitoring at 3Hrs after 1 dose, sitagliptin vs placebo</description>
        <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP), Non-invasive Cardiac Output Monitoring</title>
          <description>SBP by Non-Invasive cardiac output monitoring at 3Hrs post- study drug administration after 1 month compared to SBP by Non-invasive cardiac output monitoring at 3Hrs after 1 dose, sitagliptin vs placebo</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="9.9"/>
                    <measurement group_id="O2" value="0.0" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Regression, Linear</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.7</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Effective Renal Plasma Flow (ERPF)</title>
        <description>ERPF (para-aminohippurate clearance) 3Hrs post-study drug administration after 1 month compared to ERPF at 3Hhrs post-study drug administration after 1 dose, sitagliptin vs placebo</description>
        <time_frame>3 Hrs post-administration after 1 month and after 1 dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental Arm</title>
            <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Effective Renal Plasma Flow (ERPF)</title>
          <description>ERPF (para-aminohippurate clearance) 3Hrs post-study drug administration after 1 month compared to ERPF at 3Hhrs post-study drug administration after 1 dose, sitagliptin vs placebo</description>
          <units>ml per min per 1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="152.1"/>
                    <measurement group_id="O2" value="-24.7" spread="142.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The intention to treat population at risk was 17 for the experimental arm and 18 for the placebo arm, and the final per-protocol population was 16 per arm. 1 participant in the experimental arm was withdrawn due to lower GI bleeding after randomization, and 2 participants in the placebo arm were withdrawn, 1 due to dyspnea and 1 due to presyncope after randomization.</desc>
      <group_list>
        <group group_id="E1">
          <title>Experimental Arm</title>
          <description>sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
Placebo: Oral tablet (no medicinal ingredients) administered once daily for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>University Health Network</name_or_title>
      <organization>Renal Physiology Laboratory</organization>
      <phone>416-340-4800 ext 8508</phone>
      <email>vesta.lai@uhn.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

